Literature DB >> 9299265

Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric.

P L Hermonat1, R T Plott, A D Santin, G P Parham, J T Flick.   

Abstract

Seroepidemiologic studies demonstrate that adeno-associated virus (AAV) infection is negatively associated with cervical cancer. This inverse association may be due to an ability of AAV to inhibit the role of human papillomavirus (HPV) in cervical carcinogenesis. In support of this hypothesis AAV has been demonstrated to inhibit several papillomavirus types, including bovine papillomavirus type 1 and human papillomaviruses types 16 and 18 (HPV-16/18) in tissue culture. The AAV-encoded Rep78 protein was responsible for this inhibition. These previous studies, however, were largely carried out in immortalized mouse fibroblasts. This cell type is likely not to be the most accurate model cell type for studying HPV-associated cervical carcinogenesis. In this study it is demonstrated that AAV Rep78 protein inhibits oncogenic transformation of freshly explanted primary human foreskin keratinocytes by an HPV-16/ras chimeric genome. Such cells are the natural host cell type for HPV-16/18 infection. It is also demonstrated that the HPV-16 P97 promoter is specifically inhibited by Rep78 in a transient CAT assay. These data further extend our knowledge of the AAV-papillomavirus interaction and provide a model for investigating the negative association of AAV with cervical cancer. Copyright 1997 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299265     DOI: 10.1006/gyno.1997.4789

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  HPV E1 up-regulates replication-related biochemistries of AAV Rep78.

Authors:  Sarmistha Bandyopadhyay; Maohua Cao; Yong Liu; Paul L Hermonat
Journal:  Virology       Date:  2010-04-07       Impact factor: 3.616

2.  Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.

Authors:  Terence R Flotte
Journal:  Mol Ther       Date:  2013-11       Impact factor: 11.454

3.  Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses.

Authors:  U Bantel-Schaal; H Delius; R Schmidt; H zur Hausen
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

4.  Adeno-associated virus type 2 increases proteosome-dependent degradation of p21WAF1 in a human papillomavirus type 31b-positive cervical carcinoma line.

Authors:  Samina Alam; Ellora Sen; Heidi Brashear; Craig Meyers
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 5.  The interaction between human papillomavirus and other viruses.

Authors:  J T Guidry; R S Scott
Journal:  Virus Res       Date:  2016-11-05       Impact factor: 3.303

6.  Adeno-associated virus major Rep78 protein disrupts binding of TATA-binding protein to the p97 promoter of human papillomavirus type 16.

Authors:  P F Su; S Y Chiang; C W Wu; F Y Wu
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  AAV Infection: Protection from Cancer.

Authors:  Arun Srivastava; Barrie J Carter
Journal:  Hum Gene Ther       Date:  2016-11-10       Impact factor: 5.695

8.  Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein.

Authors:  P Ogston; K Raj; P Beard
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

9.  Infection and cervical neoplasia: facts and fiction.

Authors:  Wael I Al-Daraji; John Hf Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-04-28

10.  Cervical cancer isolate PT3, super-permissive for adeno-associated virus replication, over-expresses DNA polymerase delta, PCNA, RFC and RPA.

Authors:  Bum Yong Kang; Hong You; Sarmistha Bandyopadhyay; Nalini Agrawal; Russell B Melchert; Alexei G Basnakian; Yong Liu; Paul L Hermonat
Journal:  BMC Microbiol       Date:  2009-04-23       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.